Keros Therapeutics (KROS) Depreciation and Depletion (2019 - 2025)
Keros Therapeutics posted quarterly Depreciation and Depletion of $400000.0 for Q4 2025, up 20.48% year-on-year from $332000.0 in Q4 2024, and up 1.27% on a QoQ basis from $395000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Depreciation and Depletion data on file, last reported at $400000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation and Depletion rose 20.48% year-over-year to $400000.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 22.78% YoY), and the FY2025 full-year result was $1.5 million, up 22.78% from the prior year.
- Depreciation and Depletion for Q4 2025 stood at $400000.0, up from $395000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $400000.0 in Q4 2025 and bottomed at $80000.0 in Q1 2021.
- The 5-year median for Depreciation and Depletion is $228500.0 (2023), against an average of $230250.0.
- The widest annual swing landed in 2022, when Depreciation and Depletion surged 238.46%; it then sank 37.99% in 2023.
- A 5-year view of Depreciation and Depletion shows it stood at $104000.0 in 2021, then climbed by 22.12% to $127000.0 in 2022, then jumped by 94.49% to $247000.0 in 2023, then soared by 34.41% to $332000.0 in 2024, then increased by 20.48% to $400000.0 in 2025.
- The last three Depreciation and Depletion figures came in at $400000.0 (Q4 2025), $395000.0 (Q3 2025), and $370000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Jun 30, 2023 | 191,000.00 |
| Jun 30, 2023 | 191,000.00 |
| Mar 31, 2023 | 167,000.00 |
| Mar 31, 2023 | 167,000.00 |
| Dec 31, 2022 | 127,000.00 |
| Dec 31, 2022 | 127,000.00 |
| Sep 30, 2022 | 126,000.00 |
| Sep 30, 2022 | 126,000.00 |
| Jun 30, 2022 | 308,000.00 |
| Jun 30, 2022 | 308,000.00 |
| Mar 31, 2022 | 113,000.00 |
| Mar 31, 2022 | 113,000.00 |
| Dec 31, 2021 | 104,000.00 |
| Dec 31, 2021 | 104,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 91,000.00 |
| Jun 30, 2021 | 91,000.00 |
| Mar 31, 2021 | 80,000.00 |
| Mar 31, 2021 | 80,000.00 |
| Dec 31, 2020 | 75,000.00 |
| Dec 31, 2020 | 75,000.00 |
| Sep 30, 2020 | 72,000.00 |
| Sep 30, 2020 | 72,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Mar 31, 2020 | 63,000.00 |
| Dec 31, 2019 | 59,000.00 |
| Dec 31, 2019 | 59,000.00 |
| Sep 30, 2019 | 55,000.00 |
| Sep 30, 2019 | 55,000.00 |
| Jun 30, 2019 | 49,000.00 |
| Jun 30, 2019 | 49,000.00 |
| Mar 31, 2019 | 45,000.00 |
| Mar 31, 2019 | 45,000.00 |